A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo Controlled Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2017
At a glance
- Drugs APX 001 (Primary)
- Indications Aspergillosis; Candidiasis; Mycoses
- Focus Adverse reactions; First in man
- 31 Jul 2017 Status changed from recruiting to completed.
- 12 Sep 2016 Status changed from planning to recruiting according to an Amplyx Pharmaceuticals media release.
- 12 Dec 2015 New trial record